BioLife Solutions Inc (BLFS)

Return on total capital

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands -13,096 -27,637 -54,861 -67,346 -70,823 -106,939 -89,896 -151,179 -145,541 -114,735 -114,154 -42,146 -35,160 -22,104 -12,075 -23,900 -610 6,241 17,641 38,274
Long-term debt US$ in thousands 4,997 7,823 10,451 15,681 17,561 20,937 23,572 23,692 23,793 24,207 6,188 6,313 6,353 6,122 5,019 916 655
Total stockholders’ equity US$ in thousands 348,909 325,461 321,442 333,405 337,663 332,017 352,128 358,107 364,188 405,120 409,544 476,075 478,047 489,259 452,281 208,777 204,429 186,851 105,843 67,709
Return on total capital -3.70% -8.29% -16.53% -19.29% -19.94% -30.30% -23.93% -39.60% -37.51% -26.72% -27.46% -8.74% -7.26% -4.46% -2.64% -11.40% -0.30% 3.34% 16.67% 56.53%

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-13,096K ÷ ($4,997K + $348,909K)
= -3.70%

BioLife Solutions Inc's return on total capital has been volatile over the past few years, starting strong at 56.53% as of March 31, 2020, but declining steadily thereafter. The company experienced a significant drop to -27.46% by June 30, 2022, and continued to face negative returns in subsequent periods. As of December 31, 2024, the return on total capital improved slightly to -3.70%, but it remains negative, indicating that the company may not be generating sufficient returns on the capital invested in its operations. This trend suggests that investors and stakeholders should closely monitor the company's financial performance and strategies to address the declining return on total capital.


Peer comparison

Dec 31, 2024